Search Results
Your search for The A matches 33016 pages
Showing 31251 - 31300FDA Approves Expanded Use of Tilmanocept for Lymphatic Mapping in Solid Tumors
The U.S. Food and Drug Administration (FDA) has approved the Supplemental New Drug Application for the expanded use of technetium 99m tilmanocept (Lymphoseek Injection) for lymphatic mapping in solid tumors and for adding sentinel lymph node detection for breast cancer and melanoma to the approved...
Single-Day Education Program Mitigates Psychosexual Side Effects of Risk-Reducing Salpingo-Oophorectomy
More women are undergoing salpingo-oophorectomy as a cancer prevention measure, but many are unaware of the potential sexual or psychological side effects of the procedure. A new study by researchers at Dana-Farber Cancer Institute demonstrated that a half-day educational program can help ...
Racial Differences in the Risk of Second Breast Tumors Reported in Women With Ductal Carcinoma in Situ
Regardless of age at diagnosis, type of treatment, tumor grade or size, and tumor histology, black and Hispanic women had a higher risk of second ipsilateral breast tumors than did white women after ductal carcinoma in situ, according to the results of a large registry study presented by Liu et al...
Substantial Benefit of Intensive Surveillance Following Bimodality Therapy for Esophageal Cancer
In a study reported in the Journal of Clinical Oncology, Sudo et al found that many patients undergoing definitive chemoradiotherapy (bimodality therapy) for esophageal cancer can derive substantial survival benefit from subsequent salvage surgery, supporting a practice of intensive...
LINE-1 Hypomethylation Associated With Poorer Survival in Microsatellite Instability–High vs Microsatellite-Stable Tumors in Colorectal Cancer
In a study reported in the Journal of the National Cancer Institute, Inamura et al found that hypomethylation in long interspersed nucleotide element-1 (LINE-1) is associated with greater colorectal cancer–specific and overall mortality in high-degree microsatellite instability vs...
ASCO Endorses Guideline for Molecular Testing to Select Lung Cancer Patients for EGFR and ALK Inhibitor Treatment
ASCO has endorsed the recently developed joint College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association of Molecular Pathologists (AMP) guideline on molecular testing for selection of patients with lung cancer for EGFR and ALK inhibitor ...
FDA Grants Priority Review to Palbociclib as First-Line Therapy in Combination With Letrozole in Advanced Breast Cancer
The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to Pfizer’s New Drug Application for palbociclib, in combination with letrozole, as a first-line treatment for postmenopausal women with estrogen receptor–positive, HER2-negative advanced breast cancer...
Researchers Reveal Genomic Diversity of Individual Lung Tumors
Known cancer-driving genomic aberrations in localized lung cancer appear to be so consistently present across tumors that a single biopsy of one region of the tumor is likely to identify most of them, according to a paper published by Zhang et al in Science. The study led by scientists at The...
Hormone Loss Could Be Involved in Colon Cancer
Some cancers, like breast and prostate cancer, are driven by hormones such as estrogen and testosterone, but to date, there are none that are understood to be driven by the lack of a hormone. New evidence reported by researchers at Thomas Jefferson University, Philadelphia, suggests that human...
Adding Aprepitant to Granisetron/Dexamethasone Reduces Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan Conditioning in Myeloma
In a phase III trial reported in the Journal of Clinical Oncology, Schmitt et al found that adding aprepitant to granisetron and dexamethasone significantly reduced chemotherapy-induced nausea and vomiting in myeloma patients undergoing high-dose melphalan conditioning and autologous stem cell...
PET/CT Scanning May Provide Accurate Staging of Younger Patients With Breast Cancer
In breast cancer patients under the age of 40, positron-emission tomography/computed tomography (PET/CT) scanning may provide accurate clinical staging for stage IIB and III disease, according to the study findings presented by Riedl et al in The Journal of Nuclear Medicine. The utilization of...
Second-Line Bevacizumab/Chemotherapy Improves Progression-Free Survival in Advanced HER2-Negative Breast Cancer
In the phase III TANIA trial reported in The Lancet Oncology, von Minckwitz et al found that adding bevacizumab (Avastin) to chemotherapy in second-line treatment improved progression-free survival after first-line bevacizumab plus chemotherapy in patients with HER2-negative locally recurrent or...
Rate of Cancer Detection at Risk-Reducing Salpingo-Oophorectomy
In a study reported in the Journal of Clinical Oncology, Sherman et al found occult cancers in 2.6% of high-risk women undergoing risk-reducing salpingo-oophorectomy. Study Details The study involved 966 asymptomatic high-risk women age ≥ 30 years who underwent risk-reducing...
New Findings in Acute Promyelocytic Leukemia
Three studies reported in the Journal of Clinical Oncology provide information on maintenance treatment with the synthetic retinoid tamibarotene in acute promyelocytic leukemia, potential implications of QT interval prolongation related to arsenic trioxide (Trisenox), and potential health-related...
Blinatumomab Receives FDA Priority Review Designation in Acute Lymphoblastic Leukemia
The U.S. Food and Drug Administration (FDA) has accepted for review Amgen’s Biologics License Application for blinatumomab for the treatment of adults with Philadelphia chromosome–negative relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). As part of the acceptance, the ...
FDA Approves Bortezomib Injection for Previously Untreated Patients With Mantle Cell Lymphoma
The U.S. Food and Drug Administration (FDA) has approved bortezomib (Velcade) injection for previously untreated patients with mantle cell lymphoma. This is the first treatment in the United States to be approved for use in previously untreated patients with mantle cell lymphoma. Bortezomib was...
FDA Approves Netupitant and Palonosetron Combination Capsule for Chemotherapy-Induced Nausea and Vomiting
The U.S. Food and Drug Administration (FDA) today approved a combination of netupitant and palonosetron (Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy. The new drug, also known as NEPA, is a fixed-combination capsule comprised of two agents: oral palonosetron,...
Study Finds Potential Link Between BRCA1/2 Mutations and Salivary Gland Cancer
The risk of developing cancer in a salivary gland might be higher in people with BRCA1 or BRCA2 mutations, which are associated with breast and ovarian cancer, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital...
New Predictive Model for Lung Cancer May Improve Accuracy in Prescreening Lung Nodules Prior to Resection
An investigative predictive model for lung cancer demonstrated more accuracy than the more commonly used Mayo Clinic model in prescreening lung nodules prior to resection, according to the results of a study reported by Deppen et al in the Journal of Thoracic Oncology. The investigators suggested...
Updated GEM2005 Trial Confirms Benefit of Melphalan/Bortezomib Combination in Elderly Multiple Myeloma Patients
Melphalan in combination with bortezomib (Velcade) should be maintained as one of the standards of care for the treatment of elderly patients with multiple myeloma, concluded Spanish trialists reporting updated results from the GEM2005 study comparing bortezomib/melphalan/prednisone with...
Anti–PD-1 Antibody Pembrolizumab Is Active in Ipilimumab-Refractory Advanced Melanoma
As reported in The Lancet by Robert et al, the anti–programmed-death receptor-1 (PD-1) antibody pembrolizumab (Keytruda) produced durable responses in a phase I trial in patients with ipilimumab (Yervoy)-refractory melanoma. The study provided the basis for the recent accelerated approval of...
Study Identifies Groups at Risk for Gastrointestinal Stromal Tumors
Researchers at the University of California, San Diego, School of Medicine have, for the first time, clearly defined the epidemiology of gastrointestinal stromal tumors (GIST), which occur primarily in the lining of the stomach and small intestine. Of note was the discovery that patients of Asian...
One in Three People With Cancer Has Anxiety or Other Mental Health Challenges
Researchers in Germany report that nearly one-third of more than 2,100 patients with cancer interviewed at inpatient and outpatient care centers experienced a clinically meaningful level of mental or emotional distress that meets the strict diagnostic criteria for mental disorders including...
Overexpression of Threonyl tRNA-Synthetase Demonstrates Potential Value as a Prognostic and Therapeutic Factor in Ovarian Cancer Patients
The molecule threonyl tRNA-synthetase may provide value as a serum diagnostic marker and a potential target of therapy for ovarian cancer, according to the results of a study reported by Wellman et al in BMC Cancer. In addition, the mortality risk was slightly reduced for patients with high...
HPV 16/18 Vaccine Shows Protective Efficacy in Women Aged > 25 Years in 4-Year Interim Follow-up of VIVIANE Study
In the 4-year interim follow-up of the VIVIANE study reported in The Lancet by Skinner et al, the human papillomavirus (HPV) 16/18 AS04-adjuvanted vaccine was found to be protective against 6-month persistent infection or cervical intraepithelial neoplasia grade 1 or higher (CIN1+) associated with...
Higher Levels of Cholesterol and Triglycerides May Increase the Risk of Prostate Cancer Recurrence
Prostate cancer survivors with higher levels of total cholesterol and triglycerides had an increased risk for disease recurrence, according to a study by Allott et al. The study findings, coupled with evidence that statin use is associated with reduced recurrence risk, suggest that lipid levels...
New Mutations Found in Anaplastic Thyroid Cancer Lead to Dramatic Response and Acquired Resistance to Everolimus
A study involving a patient with metastatic anaplastic thyroid cancer who achieved a near-complete response to everolimus (Afinitor) that lasted for 18 months, followed by progressive disease, has revealed a previously unknown mutation in the TSC2 gene and in the mTOR protein. The discovery...
Fiber-Based Laxatives Linked to Decreased Risk of Colorectal Cancer
A large, prospective study involving more than 75,000 adults in western Washington has found that frequent use of fiber-based laxatives is associated with a decreased risk of colorectal cancer. The study also found that use of nonfiber laxatives is linked to significantly increased risk of...
After Adjustment for Stage at Diagnosis, No Difference Evident in Melanoma-Specific Mortality Between Amelanotic and Pigmented Melanomas
In a large international population-based study reported in JAMA Dermatology, Thomas et al found that increased risk of melanoma-related mortality for patients with amelanotic vs those with pigmented melanomas was no longer evident after adjustment for tumor stage at diagnosis. The study involved...
Adjuvant Radiotherapy Benefits Survival in Subsets of Patients With Node-Positive Prostate Cancer
In an analysis of outcomes in patients with node-positive prostate cancer reported in the Journal of Clinical Oncology, Abdollah et al found that adjuvant radiotherapy is associated with a survival benefit in patients with low-volume nodal disease in the setting of intermediate- to high-grade...
Abiraterone Acetate/Prednisone in Metastatic Castration-Resistant Prostate Cancer: Final Analysis of Early-Access Protocol Study
Abiraterone acetate (Zytiga) is approved for use in combination with prednisone in the treatment of metastatic castration-resistant prostate cancer. As reported by Sternberg et al in The Lancet Oncology, results of an open-label, early-access protocol trial initiated prior to approval indicated no...
FDA Grants Orphan Drug Designation to DNX-2401 for Malignant Glioma
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to DNAtrix’s DNX-2401, a conditionally-replicative oncolytic adenovirus for malignant glioma. Glioma is the most common form of primary brain cancer, the treatment of which remains a significant unmet medical...
2014 Nobel Prize in Physiology or Medicine Awarded to John O’Keefe, FRS, May-Britt Moser, PhD, and Edvard I. Moser, PhD
The Nobel Assembly at Karolinska Institutet has awarded the 2014 Nobel Prize in Physiology or Medicine to John O’Keefe, FRS, and to May-Britt Moser, PhD, and Edvard I. Moser, PhD, for their discoveries of cells that constitute a positioning system in the brain. This “inner GPS”...
AR-V7 in Circulating Tumor Cells Associated With Resistance to Enzalutamide and Abiraterone in Prostate Cancer
The androgen receptor isoform encoded by splice variant 7 is constitutively active as a transcription factor, despite lacking the ligand-binding domain that is the target of enzalutamide (Xtandi) and abiraterone (Zytiga). In a study reported in The New England Journal of Medicine, Antonarakis et al ...
Increased Risk of Fracture After Radical Cystectomy and Urinary Diversion in Older Patients With Bladder Cancer
In a population-based study reported in the Journal of Clinical Oncology, Gupta et al found that radical cystectomy with urinary diversion for bladder cancer is associated with increased risk of bone fracture at any site in Medicare patients. Radical cystectomy and urinary diversion may cause...
No Increased Risk of Ovarian Cancer With Perineal Powder Use
Perineal powder use has been associated with increased risk of ovarian cancer in case-control studies and with increased risk of serous invasive ovarian cancer in a cohort study. In a large cohort study reported in the Journal of the National Cancer Institute, Houghton et al found no significant...
Study Finds Increase in Colonoscopy Rates Has Lead to Overuse
A retrospective study led by researchers at Brigham and Women's Hospital has found an overuse of colonoscopies for colorectal cancer screening and surveillance. The study demonstrated that endoscopists commonly recommended shorter follow-up intervals than established guidelines support, and these...
TERT Promoter Mutation Associated With Reduced Survival in Nonacral Cutaneous Melanoma
TERT promoter mutations have been found to occur at high frequency in cutaneous melanoma tumor samples, exhibit a UV-signature, and lead to increased TERT gene expression. In a study reported in the Journal of the National Cancer Institute, Griewank et al found that TERT promoter mutation was...
FDA Grants Orphan Drug Designation to Investigational Agent for Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to pegylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer. Halozyme Therapeutics is currently investigating PEGPH20 in a phase II study in combination with gemcitabine and...
Swedish Study Indicates No Increased Risk of Breast Cancer With 5 Years of Continuous Exposure to Calcium Channel Blockers
A recently reported U.S. population-based case-control study in women aged 55 to 74 years indicated that current use of calcium channel blockers for ≥ 10 years was associated with increased risk of ductal breast cancer (odds ratio [OR] = 2.4) and lobular breast cancer. In a Swedish case-control...
Comorbidity Associated With Shorter Overall Survival but Not With Time to Relapse or Toxicity in Older Women on Adjuvant Chemotherapy
In the Cancer and Leukemia Group B (CALGB) 70103 study, comorbidity was associated with shorter overall survival among older women with early-stage breast cancer and good functional status receiving adjuvant chemotherapy. “The presence of four or more conditions appeared to be a threshold for ...
FDG-PET Is Less Specific in Diagnosing Lung Cancer in Areas With Endemic Infectious Lung Disease
Although positron-emission tomography (PET) combined with 18F–fluorodeoxyglucose (FDG) is recommended for the noninvasive diagnosis of pulmonary nodules suspicious for lung cancer, in populations with endemic infectious lung disease, FDG-PET may not accurately identify malignant lesions. An...
Enhanced Benefit Shown With FOLFIRI/Ziv-Aflibercept in Subset of Patients With Metastatic Colorectal Cancer
The survival benefit demonstrated in the VELOUR study for FOLFIRI (irinotecan, fluorouracil [5-FU], leucovorin) plus ziv-aflibercept (Zaltrap) vs FOLFIRI plus placebo in metastatic colorectal cancer patients who had disease progression on oxaliplatin-based chemotherapy persisted beyond median...
Researchers Discover Genetic Variant That Can Predict Aggressive Prostate Cancer at Diagnosis
Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker adjacent to the KLK3 gene that can predict which prostate cancer patients with a Gleason score of 7 will have a more aggressive form of cancer. The findings by He et al, published in Clinical Cancer...
FDA Grants Breakthrough Therapy Designation to AP26113 for ALK-Positive NSCLC
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Ariad Pharmaceutical’s investigational agent AP26113 for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small cell lung cancer (NSCLC) who are resistant to crizotinib...
PET-CT as Standard for Response Assessment After First-Line Therapy in Follicular Lymphoma
In a pooled analysis reported in The Lancet Haematology, Trotman et al found that 18F-fluorodeoxyglucose (FDG) positron-emission tomography/low-dose computed tomography (PET-CT) provides improved prognostic information over conventional contrast-enhanced CT in assessment of response to first-line...
Sex Steroid Hormones May Play a Role in the Development of Aggressive Prostate Cancer
Men with higher estradiol-to-testosterone ratios had a substantially reduced risk of aggressive prostate cancer, whereas men with higher ratios of 2-hydroxyestrone to 16α-hydroxyestrone had an increased risk of such cancer, according to the study findings presented by Black et al in Cancer...
Dutch Study Finds No Increased Risk of Cardiovascular Mortality in 5-Year Survivors of DCIS
In a Dutch study reported in the Journal of the National Cancer Institute, Boekel et al found no increase in risk of cardiovascular mortality among 5-year survivors of ductal carcinoma in situ (DCIS) compared with the general population. Among DCIS patients, risk of cardiovascular events did not...
Chemoradiotherapy vs Radiotherapy Alone Linked to Increased Risk of Subsequent Malignancies in Long-Term Survivors of Hereditary Retinoblastoma
Increased risk of subsequent malignant neoplasms has been reported in hereditary retinoblastoma survivors after radiotherapy. In a study reported in Journal of Clinical Oncology, Wong et al found that chemotherapy plus radiotherapy was associated with increased risk of subsequent malignant...
Reduced Local Recurrence With Intensity-Modulated vs External-Beam Radiation Therapy in Primary Soft-Tissue Sarcomas of the Extremity
There are no large-scale direct comparisons of outcomes with intensity-modulated radiation therapy vs conventional external-beam radiation therapy in patients with soft-tissue sarcoma of the extremity. In a single-institution experience reported in the Journal of Clinical Oncology, Folkert et al at ...
